Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate.

Shah PJ, Dinsmore W, Oakes RA, Hackett G

Current medical research and opinion1 Oct 2007Cited by 15 (Europe PMC)

PMID17875241DOI10.1185/030079907x233232PepBankPUB-17875241

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

01HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneRandomized controlled trialEfficacy outcome
In men with erectile dysfunction, fewer men had a suitable erection with VIP/phentolamine than with alprostadil (73% vs. 83%) in the first phase.
In plain wordsIn men with erectile dysfunction, injections of VIP with phentolamine gave a suitable erection in fewer men than alprostadil did.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseResponse with a grade 3 erection in phase 1
Study
n = 187
Comparator
Alprostadil
Outcome group
Sexual function · Reproductive and sexual health
Measurements
Responders
73%
VIP/phentolamine
Responders
83%
alprostadil
Source sentences
Summary
In the first phase, both treatments were effective, (83% alprostadil vs. 73% VIP/phentolamine, p = 0.002)
1 context sentence(design, population, supporting numbers)
Summary · context
This was an open multicentre, randomised crossover study comprising two phases.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1787524101
02HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneRandomized controlled trialEfficacy outcome
In men with erectile dysfunction, more patients preferred VIP/phentolamine than alprostadil in the first phase (69% vs. 31%).
In plain wordsIn men with erectile dysfunction, more men preferred VIP with phentolamine than alprostadil.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePatient preference in phase 1
Study
n = 187
Comparator
Alprostadil
Outcome group
Sexual function · Reproductive and sexual health
Measurements
Preference
69%
VIP/phentolamine
Preference
31%
alprostadil
Source sentences
Summary
but more patients preferred VIP/phentolamine (69 vs. 31%, p = 0.011).
1 context sentence(design, population, supporting numbers)
Summary · context
This was an open multicentre, randomised crossover study comprising two phases.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1787524102
03HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneRandomized controlled trialEfficacy outcome
In men with erectile dysfunction, the proportion of injections that gave a grade 3 erection was similar for VIP/phentolamine (ampoule and autoinjector) and alprostadil in phase 2.
In plain wordsIn men with erectile dysfunction, VIP with phentolamine and alprostadil gave a suitable erection in a similar share of injections.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeInjections producing a grade 3 erection in phase 2
Study
n = 107
Comparator
Alprostadil
Outcome group
Sexual function · Reproductive and sexual health
Measurements
Injections with grade 3 erection
83 to 85%
all three treatments
Source sentences
Summary
In phase 2 (n = 107), the proportion of injections that produced a grade 3 erection was similar for all three treatments (83-85%)
1 context sentence(design, population, supporting numbers)
Summary · context
This was an open multicentre, randomised crossover study comprising two phases.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1787524103
04HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneRandomized controlled trialEfficacy outcome
In men with erectile dysfunction, both presentations of VIP/phentolamine were preferred by significantly more patients than alprostadil in phase 2.
In plain wordsIn men with erectile dysfunction, more men preferred both forms of VIP with phentolamine than alprostadil.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePatient preference in phase 2
Study
n = 107
Comparator
Alprostadil
Outcome group
Sexual function · Reproductive and sexual health
Source sentences
Summary
but both presentations of VIP/phentolamine (ampoule and auto-injector) were preferred by significantly more patients (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was an open multicentre, randomised crossover study comprising two phases.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1787524104
05HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneRandomized controlled trialSafety outcome
In men with erectile dysfunction, pain occurred in fewer injections of VIP/phentolamine (3%) than of alprostadil (28%).
In plain wordsIn men with erectile dysfunction, injections of VIP with phentolamine caused pain less often than alprostadil injections.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreasePain at injection
Study
n = 107
Comparator
Alprostadil
Outcome group
Adverse events · Reproductive and sexual health
Measurements
Injections with pain
3%
VIP/phentolamine
Injections with pain
28%
alprostadil
Source sentences
Summary
Compared with both presentations of VIP/phentolamine, alprostadil produced a higher frequency of pain (28% of injections vs. 3% for each VIP/phentolamine presentation; p < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
This was an open multicentre, randomised crossover study comprising two phases.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1787524105
06HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneRandomized controlled trialSafety outcome
In men with erectile dysfunction, facial flushing occurred in more injections of VIP/phentolamine (16-17%) than of alprostadil (3%).
In plain wordsIn men with erectile dysfunction, injections of VIP with phentolamine caused facial flushing more often than alprostadil injections.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseFacial flushing
Study
n = 107
Comparator
Alprostadil
Outcome group
Adverse events · Reproductive and sexual health
Measurements
Injections with facial flushing
16 to 17%
VIP/phentolamine
Injections with facial flushing
3%
alprostadil
Source sentences
Summary
a lower frequency of facial flushing (3 vs. 16-17%; p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was an open multicentre, randomised crossover study comprising two phases.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1787524106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.